APOE2 Exacerbates TDP‐43 Related Toxicity in the Absence of Alzheimer Pathology
暂无分享,去创建一个
D. Dickson | P. McLean | Na Zhao | Wenhui Qiao | M. DeTure | O. Ross | N. Finch | A. Kurti | M. van Blitterswijk | S. Koga | L. White | J. O'leary | M. Delenclos | Long-Jun Wu | Fuyao Li | Tadafumi C. Ikezu | Zonghua Li | G. Bu | Manling Xie | A. Murakami | Axel D. Meneses | Kai Chen | Cynthia Linares | Yixing Chen | R. Rademakers | Nicholas B. Martin | Melina J. Lim | Michael G Heckman | Aishe Kurti | Nicholas B Martin
[1] David J. Calkins,et al. Solving neurodegeneration: common mechanisms and strategies for new treatments , 2022, Molecular Neurodegeneration.
[2] P. van Damme,et al. The role of inflammation in neurodegeneration: novel insights into the role of the immune system in C9orf72 HRE-mediated ALS/FTD , 2022, Molecular neurodegeneration.
[3] G. Sobue,et al. Motor neuron TDP-43 proteinopathy in progressive supranuclear palsy and corticobasal degeneration. , 2022, Brain : a journal of neurology.
[4] D. Bosco,et al. Microglial TREM2 in amyotrophic lateral sclerosis , 2021, Developmental neurobiology.
[5] D. Dickson,et al. TDP-43 Pathology in Alzheimer’s Disease , 2021, Molecular neurodegeneration.
[6] D. Dickson,et al. Concurrent tau pathologies in frontotemporal lobar degeneration with TDP‐43 pathology , 2021, bioRxiv.
[7] L. Petrucelli,et al. Cellular and pathological heterogeneity of primary tauopathies , 2021, Molecular neurodegeneration.
[8] Tau En Lim,et al. Plaque-associated human microglia accumulate lipid droplets in a chimeric model of Alzheimer’s disease , 2021, Molecular neurodegeneration.
[9] Timothy J. Hohman,et al. Protective genes and pathways in Alzheimer’s disease: moving towards precision interventions , 2021, Molecular Neurodegeneration.
[10] F. Svensson,et al. TREM2/PLCγ2 signalling in immune cells: function, structural insight, and potential therapeutic modulation , 2021, Molecular Neurodegeneration.
[11] M. Mattson,et al. TREM2 interacts with TDP-43 and mediates microglial neuroprotection against TDP-43-related neurodegeneration , 2021, bioRxiv.
[12] G. Bu,et al. APOE2: protective mechanism and therapeutic implications for Alzheimer’s disease , 2020, Molecular Neurodegeneration.
[13] M. Selenica,et al. TDP-43 mediated blood-brain barrier permeability and leukocyte infiltration promote neurodegeneration in a low-grade systemic inflammation mouse model , 2020, Journal of neuroinflammation.
[14] T. Goldberg,et al. Association of APOE e2 genotype with Alzheimer’s and non-Alzheimer’s neurodegenerative pathologies , 2020, Nature Communications.
[15] Michelle K. Cahill,et al. Neurotoxic microglia promote TDP-43 proteinopathy in progranulin deficiency , 2020, Nature.
[16] Maxime W. C. Rousseaux,et al. The role of TDP-43 mislocalization in amyotrophic lateral sclerosis , 2020, Molecular Neurodegeneration.
[17] Huaxi Xu,et al. Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease , 2020, Molecular Neurodegeneration.
[18] Y. Asmann,et al. Alzheimer’s Risk Factors Age, APOE Genotype, and Sex Drive Distinct Molecular Pathways , 2020, Neuron.
[19] J. Grutzendler,et al. TREM2: Modulator of Lipid Metabolism in Microglia , 2020, Neuron.
[20] Y. Asmann,et al. APOE4 exacerbates α-synuclein pathology and related toxicity independent of amyloid , 2020, Science Translational Medicine.
[21] D. Markusic,et al. Immune Response Mechanisms against AAV Vectors in Animal Models , 2019, Molecular therapy. Methods & clinical development.
[22] G. Bu,et al. Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies , 2019, Nature Reviews Neurology.
[23] D. Dickson,et al. The neuropathological diagnosis of Alzheimer’s disease , 2019, Molecular Neurodegeneration.
[24] C. Jack,et al. Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report , 2019, Brain : a journal of neurology.
[25] D. Fardo,et al. Tau and TDP-43 proteinopathies: kindred pathologic cascades and genetic pleiotropy , 2019, Laboratory Investigation.
[26] D. Dickson,et al. TDP‐43 pathology in multiple system atrophy: colocalization of TDP‐43 and α‐synuclein in glial cytoplasmic inclusions , 2018, Neuropathology and applied neurobiology.
[27] P. Schulz,et al. Disease-modifying effects of metabolic perturbations in ALS/FTLD , 2018, Molecular neurodegeneration.
[28] L. Petrucelli,et al. Association of Apolipoprotein E &egr;4 With Transactive Response DNA-Binding Protein 43 , 2018, JAMA neurology.
[29] Charles C. White,et al. Evaluation of TDP-43 proteinopathy and hippocampal sclerosis in relation to APOE ε4 haplotype status: a community-based cohort study , 2018, The Lancet Neurology.
[30] B. Boeve,et al. Corticobasal degeneration with TDP-43 pathology presenting with progressive supranuclear palsy syndrome: a distinct clinicopathologic subtype , 2018, Acta Neuropathologica.
[31] John L. Robinson,et al. Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated , 2018, Brain : a journal of neurology.
[32] G. Bu,et al. Apolipoprotein E, Receptors, and Modulation of Alzheimer’s Disease , 2018, Biological Psychiatry.
[33] A. Chen-Plotkin,et al. Genetic Modifiers in Neurodegeneration , 2018, Current Genetic Medicine Reports.
[34] J. Trojanowski,et al. Microglia-mediated recovery from ALS-relevant motor neuron degeneration in a mouse model of TDP-43 proteinopathy , 2018, Nature Neuroscience.
[35] Markus Glatzel,et al. The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases. , 2017, Immunity.
[36] A. Goate,et al. A Tale of Two Genes: Microglial Apoe and Trem2. , 2017, Immunity.
[37] John L. Robinson,et al. Neuron loss and degeneration in the progression of TDP-43 in frontotemporal lobar degeneration , 2017, Acta neuropathologica communications.
[38] I. Amit,et al. A Unique Microglia Type Associated with Restricting Development of Alzheimer’s Disease , 2017, Cell.
[39] J. Hardy,et al. Gene-based association studies report genetic links for clinical subtypes of frontotemporal dementia , 2017, Brain : a journal of neurology.
[40] D. Holtzman,et al. Elucidating the Role of TREM2 in Alzheimer’s Disease , 2017, Neuron.
[41] Wenzhang Wang,et al. Motor-Coordinative and Cognitive Dysfunction Caused by Mutant TDP-43 Could Be Reversed by Inhibiting Its Mitochondrial Localization. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.
[42] A. Chiò,et al. The Role of APOE in the Occurrence of Frontotemporal Dementia in Amyotrophic Lateral Sclerosis. , 2016, JAMA neurology.
[43] Sara Zarei,et al. A comprehensive review of amyotrophic lateral sclerosis , 2015, Surgical neurology international.
[44] R. Klein,et al. AAV9 supports wide-scale transduction of the CNS and TDP-43 disease modeling in adult rats , 2015, Molecular therapy. Methods & clinical development.
[45] S. Younkin,et al. Apolipoprotein E Is a Ligand for Triggering Receptor Expressed on Myeloid Cells 2 (TREM2)* , 2015, The Journal of Biological Chemistry.
[46] M. Farzan,et al. The Triggering Receptor Expressed on Myeloid Cells 2 Binds Apolipoprotein E* , 2015, The Journal of Biological Chemistry.
[47] J. Trojanowski,et al. Functional recovery in new mouse models of ALS/FTLD after clearance of pathological cytoplasmic TDP-43 , 2015, Acta Neuropathologica.
[48] S. Murayama,et al. Incidence and extent of TDP-43 accumulation in aging human brain , 2015, Acta neuropathologica communications.
[49] Murray Grossman,et al. Frontotemporal lobar degeneration: defining phenotypic diversity through personalized medicine , 2015, Acta Neuropathologica.
[50] C. Jack,et al. TDP-43 is a key player in the clinical features associated with Alzheimer’s disease , 2014, Acta Neuropathologica.
[51] L. Pinessi,et al. Apolipoprotein E polymorphisms in frontotemporal lobar degeneration: A meta-analysis , 2013, Alzheimer's & Dementia.
[52] D. Burns,et al. TDP-43, an ALS Linked Protein, Regulates Fat Deposition and Glucose Homeostasis , 2013, PloS one.
[53] Jianbin Tong,et al. Mutant TDP-43 in motor neurons promotes the onset and progression of ALS in rats. , 2012, The Journal of clinical investigation.
[54] Charles D. Smith,et al. Hippocampal sclerosis in advanced age: clinical and pathological features. , 2011, Brain : a journal of neurology.
[55] Jernej Ule,et al. TDP‐43 regulates its mRNA levels through a negative feedback loop , 2011, The EMBO journal.
[56] D. Price,et al. Deletion of TDP-43 down-regulates Tbc1d1, a gene linked to obesity, and alters body fat metabolism , 2010, Proceedings of the National Academy of Sciences.
[57] Guojun Bu,et al. Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy , 2009, Nature Reviews Neuroscience.
[58] J. Trojanowski,et al. Concomitant TAR-DNA-Binding Protein 43 Pathology Is Present in Alzheimer Disease and Corticobasal Degeneration but Not in Other Tauopathies , 2008, Journal of neuropathology and experimental neurology.
[59] D. Dickson,et al. TDP‐43 immunoreactivity in hippocampal sclerosis and Alzheimer's disease , 2007, Annals of neurology.
[60] Bruce L. Miller,et al. Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis , 2006, Science.
[61] Jennifer Farmer,et al. Frontotemporal dementia: Clinicopathological correlations , 2006, Annals of neurology.
[62] B. Dubois,et al. Apolipoprotein E gene in frontotemporal dementia: an association study and meta-analysis , 2002, European Journal of Human Genetics.